Latest filing published 09 Feb 2026 for Spero Therapeutics, Inc., €37k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Timothy Keutzer is a declared insider of Spero Therapeutics, Inc. (senior executive), with filings sourced from SEC (Form 4). Over a trading history stretching from 26 August 2021 to 6 February 2026, the count stands at 18 filings.
On the market, this insider has only sold: 12 sales, €218k in total. Besides market trades, the filings include 6 share grants. So far in 2026, the count stands at no purchases and 4 sales.
Most recently, on 9 February 2026, the filings show an open-market sale worth €37k in Spero Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations